Cocrystals: Molecular Design of Pharmaceutical Materials

Pharmaceutical Cocrystals: An Overview

In the last few years, a large number of drugs have been discovered with low aqueous solubility. Among these recently discovered drugs, about 60-70% of the compounds are related to the BCS Class II (low solubility/high permeability) and IV (low solubility/ low permeability)[1,2]. Many active pharmaceutical ingredients (APIs) have not been developed in formulations due to low aqueous solubility,...

Towards more Efficient Screening of Pharmaceutical Cocrystals

Pharmaceutical Cocrystals and Their Physicochemical Properties

This review article will highlight and discuss the advances made over the last 10 years pertaining to physical and chemical property improvements through pharmaceutical cocrystals and, hopefully, draw closer the fields of crystal engineering and pharmaceutical sciences.

Pharmaceutical cocrystals of diflunisal and diclofenac with theophylline.

Pharmaceutical cocrystals of nonsteroidal anti-inflammatory drugs diflunisal (DIF) and diclofenac (DIC) with theophylline (THP) were obtained, and their crystal structures were determined. In both of the crystal structures, molecules form a hydrogen bonded supramolecular unit consisting of a centrosymmetric dimer of THP and two molecules of active pharmaceutical ingredient (API). Crystal lattic...

An overview of pharmaceutical cocrystals as intellectual property.

This review article focuses on the interaction among certain scientific, legal, and regulatory aspects of pharmaceutical crystal forms. The article offers an analysis of pharmaceutical cocrystals as patentable inventions by drawing upon recent scientific developments in the field. Several potential commercial advantages of pharmaceutical cocrystals are highlighted, and a number of recent court ...